Barry J. Allen
Centre for Experimental Radiation Oncology
St George Cancer Care Centre
Kogarah
New South Wales
Australia
Name/email consistency: high
- Intralesional targeted alpha therapy for metastatic melanoma. Allen, B.J., Raja, C., Rizvi, S., Li, Y., Tsui, W., Graham, P., Thompson, J.F., Reisfeld, R.A., Kearsley, J. Cancer Biol. Ther. (2005)
- Preclinical studies of targeted alpha therapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2. Allen, B.J., Tian, Z., Rizvi, S.M., Li, Y., Ranson, M. Br. J. Cancer (2003)
- Production of terbium-152 by heavy ion reactions and proton induced spallation. Allen, B.J., Goozee, G., Sarkar, S., Beyer, G., Morel, C., Byrne, A.P. Appl. Radiat. Isot (2001)
- Preclinical targeted alpha therapy for subcutaneous melanoma. Allen, B.J., Rizvi, S.M., Tian, Z. Melanoma Res. (2001)
- In vitro and preclinical targeted alpha therapy for melanoma, breast, prostate and colorectal cancers. Allen, B.J., Rizvi, S., Li, Y., Tian, Z., Ranson, M. Crit. Rev. Oncol. Hematol. (2001)
- Targeted alpha therapy: evidence for potential efficacy of alpha-immunoconjugates in the management of micrometastatic cancer. Allen, B.J. Australas. Radiol (1999)
